Who Paid My Doc
Zachary Threlkeld
Neurocritical Care Stanford, CA Medical Doctor
NPI 1639445372 CMS profile 609263
300 Pasteur Dr, Stanford, CA 94305
General payments
$102
Research payments
$1,108
Ownership & investment interest
$0
Through program year 2024, Zachary Threlkeld of Stanford, CA is reported in the CMS Open Payments database as having received $102 across 1 general payment and $1,108 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 80th percentile of Neurocritical Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $102 | 1 | |
| 2019 | Research | $1,108 | 1 |
Beside peers
- Zachary Threlkeld
- Neurocritical Care median
- Middle half of Neurocritical Care
- National median
In program year 2025, general payments to Zachary Threlkeld were reported at $0. Among 223 Neurocritical Care profiles paid that year, the median was $98 and the middle half received between $34 and $262.
Show as a table
| Year | Zachary Threlkeld | Neurocritical Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $125 | $47–$286 | $163 |
| 2020 | $0 | $74 | $21–$153 | $114 |
| 2021 | $0 | $108 | $34–$250 | $132 |
| 2022 | $0 | $115 | $31–$277 | $149 |
| 2023 | $0 | $127 | $35–$275 | $160 |
| 2024 | $102 | $127 | $44–$265 | $164 |
| 2025 | $0 | $98 | $34–$262 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 3 billing codesPaid by Medicare
$33,997
Medicare patients
88
Services billed
203
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 50% | |
| Ischemic heart disease | 49% | |
| Chronic kidney disease | 48% | |
| Atrial fibrillation | 42% | |
| Heart failure | 40% | |
| Depression | 38% | |
| Arthritis | 38% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurocritical Care in California
Nerses Sanossian
Neurocritical Care · Los Angeles, CA
May Kim-Tenser
Neurocritical Care · Los Angeles, CA
Wengui Yu
Neurocritical Care · Orange, CA
Marion Buckwalter
Neurocritical Care · Stanford, CA
Johannes Pulst-Korenberg
Neurocritical Care · Los Angeles, CA
Arash Afshinnik
Neurocritical Care · Fresno, CA
Related records
Neurocritical Care in California
Practitioners in the same specialty and state, ranked by reported value.
All Neurocritical Care
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.